Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.80 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | MEN1 | O00255 | 3/20 | 0.80 |
| ▸ | HTT | P42858 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 1/20 | 0.80 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.74 |
| ▸ | IDH1 | O75874 | 1/20 | 0.67 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | BAZ1A | Q9NRL2 | 1/20 | 0.61 |
| ▸ | MTOR | P42345 | 1/20 | 0.61 |
| ▸ | BRAF | P15056 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.61 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261676 | 0.92 | MAPK14 (0.74) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL6431565 | 0.90 | MAPT (0.77) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17609423 | 0.89 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL30069239 | 0.89 | MAPT (1.00) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL5597699 | 0.87 | KMT2A (0.90) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL30101230 | 0.87 | KMT2A (0.90) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL17664178 | 0.87 | MAPT (0.73) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL8461120 | 0.87 | MAPT (0.75) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL10217915 | 0.87 | KMT2A (0.88) | KMT2AMAPTMEN1HTTRAB9A | |
| SCHEMBL4548162 | 0.86 | KMT2A (0.87) | KMT2AMAPTMEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | claimed |
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | POSEIDON PHARMACEUTICALS A/S (DK) | 2005-04-14 | — | — | US | disclosed |
| US-20030148269-A1 | Centrifugally-enhanced method of determining ligand/target affinity | HOLZMAN THOMAS F (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080112-A1 | Compounds for use in disorders associated with mast cell or basophil acitvity | CPA3, HNMT, CMA1 | KMT2A 1345/4885MAPT 1603/4885MEN1 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.